Report: Payers may want more biosimilar data

Payers may be more demanding about biosimilars data than regulators prove to be, a report from Decision Resources says. Apparently, payers are questioning whether the FDA's requirements will answer all of their questions about bioequivalence of branded biotech meds and other companies' copycat versions. Report

Suggested Articles

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.

The custodial measure came after Chinese customs officials raided Genscript’s businesses for “suspected violations of import and export regulations.”